Figure 3:

The most common HER2 variants in the tyrosine kinase domain are activating mutations. (A-C) Cell viability of stable Ba/F3 cell lines expressing HER2 exon 19 (A), HER2 exon 20 (B), and HER2 exon 21 (C) mutations grown in IL-3 free conditions for 15 days. Fluorescence values were normalized to day zero, and the mean fold change ± SEM is plotted for each cell line (n = 3). (D-F) Representative Western blot of Ba/F3 cells expressing HER2 exon 19 (D), HER2 exon 20 (E), and HER2 exon 21 mutants (F) or empty vector (n = 3). See also Figure S2.